Are we close to targeted treatments for Huntington’s disease? NO
Authors:
doc. MUDr. Marek Baláž, Ph.D.
Authors‘ workplace:
FN u sv. Anny v Brně
; I. neurologická klinika LF MU
Published in:
Cesk Slov Neurol N 2020; 83/116(3): 241
Category:
Controversions
Sources
1. Ustohal L, Obdržálková M, Víchová M. Huntingtonova choroba jako neuropsychiatrický problém. Psychiatr praxi 2018; 19 (2): 64–66.
2. Wild EJ, Tabrizi SJ. One decade ago, one decade ahead in huntington‘s disease. Mov Disord 2019; 34 (10): 1434–1439. doi: 10.1002/mds.27849.
3. Testa CM, Jankovic J. Huntington disease: a quarter century of progress since the gene discovery. J Neurol Sci 2019; 396 : 52–68. doi: 10.1016/j.jns.2018.09.022.
4. Travessa AM, Rodrigues FB, Mestre TA et al. Fifteen years of clinical trials in Huntington‘s disease: a very low clinical drug development success rate. J Huntingtons Dis 2017; 6 (2): 157–163. doi: 10.3233/JHD-170245.
Labels
Paediatric neurology Neurosurgery NeurologyArticle was published in
Czech and Slovak Neurology and Neurosurgery
2020 Issue 3
- Hope Awakens with Early Diagnosis of Parkinson's Disease Based on Skin Odor
- Memantine Eases Daily Life for Patients and Caregivers
- Memantine in Dementia Therapy – Current Findings and Possible Future Applications
- Metamizole vs. Tramadol in Postoperative Analgesia
- Deep stimulation of the globus pallidus improved clinical symptoms in a patient with refractory parkinsonism and genetic mutation
Most read in this issue
- Glioblastoma grade IV – long-term survival
- Primary progressive aphasia
- Headaches in pregnancy
- Cognitive disorders in children with epilepsy